Agenus Reports 39% Two-Year Survival with BOT/BAL Immunotherapy Across Multiple Refractory Solid Tumors at ESMO 2025
Agenus Inc. has announced new clinical data on its combination immunotherapy, botensilimab (BOT) and balstilimab $(BAL)$, at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The results, presented in an oral session, showed that approximately 39% of late-stage, refractory solid tumor patients treated with BOT/BAL were alive at two years. The study included data from 411 patients across more than five cancer types, with 61% having received three or more prior lines of therapy. Additional poster presentations at ESMO 2025 highlighted clinical activity in hard-to-treat cancers, including cervical cancer, MSS metastatic colorectal cancer (mCRC), and non-melanoma skin cancer. The findings support ongoing and future randomized trials, such as the phase 3 BATTMAN trial, and have contributed to the authorization of BOT/BAL for compassionate use in France for patients with refractory MSS mCRC.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251017753429) on October 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.